Entity family
Clinical therapies and care approaches used to manage a condition. Examples include immunotherapy, radiotherapy, rehabilitation.
This treatment is selected. Its supporting articles are shown below.
…and its surface localization enables immune-mediated targeting. Chimeric antigen receptor T-cell (CAR-T) therapy directed against GPC3 has shown early antitumor activity in pha…
…Introduction Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of haematological malignancies. I…
…Introduction Chimeric antigen receptor T-cell (CAR-T) therapy is emerging as a novel approach for systemic sclerosis (SSc). W…
…lophosphamide. However, 10–20% of patients relapse after AHSCT. Chimeric Antigen Receptor T-cell (CAR-T) therapy is a promising treatment for SSc but has not been evaluated as …
…Background and Importance Chimeric Antigen Receptor T-cell (CAR-T) therapy has improved outcomes in relapsed or refractory haematological …
…sed evidence on the clinical efficacy, safety and durability of chimeric antigen receptor T-cell (CAR-T) therapy in autoimmune rheumatic diseases.Methods We conducted a systema…
…Background Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionised the treatment of haematological malignancies…
…Background Chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) represent two major advances …
…Background Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed treatments for hematologic malignancies, but ef…
…sociated cognitive impairment is common in patients who receive chimeric antigen receptor T-cell (CAR-T) therapy. Hence, monitoring cognitive function is vital to guide treatme…
…Background Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape of haematological malig…
…Objectives Chimeric Antigen Receptor T-cell (CAR-T) therapy is a complex, novel treatment for patients with relapsed/refrac…